Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (September 2021)
32 slides from Immunome's investor presentation, Sep 21, 2021
Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics
Harnessing the Human Memory B Cell Response To Develop Antibody- Based Therapeutics September 21, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com Copyright © 2021 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation includes certain disclosures that contain “forward-looking statements” This document may contain product names, trade names, trademarks and service marks intended to qualify for the “safe harbor” from liability established by the Private S
Slide 3: Experienced Management Team
Experienced Management Team Purnanand Sarma, PhD Former CEO of Taris Biomedical President & CEO Sold to Johnson & Johnson in 2019 Corleen Roche Former US CFO Biogen Chief Financial Officer Former CFO, Global Vaccines, Wyeth/Pfizer Dennis Giesing, PhD Former CSO at Taris Biomedical Chief Development
Slide 4: Immunome At A Glance: Proprietary Discovery Engine
Immunome “At A Glance” ADVANCING CLINICAL PROGRAMS IMM-BCP-01 Treatment of COVID-19 IND Submission Q4 2021 • Three antibody cocktail Topline Data H1 2022 • Binds to three non-overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization Proprietary • Potent Effector Function
Slide 5: Immunome Development Pipeline and Anticipated Key Milestones
Immunome Development Pipeline and Anticipated Key Milestones PRODUCT CANDIDATE ANTICIPATED ANTI-INFECTIVES TARGET DISCOVERY PRECLINICAL DESCRIPTION MILESTONE Three SARS- Three antibody IMM-BCP-01 IND filing Q4 2021 CoV-2 Epitopes cocktail PRODUCT CANDIDATE ANTICIPATED ONCOLOGY TARGET DISCOVERY PRECL
Slide 6: Proprietary Discovery Engine
Proprietary Discovery Engine Patient Sampling Ongoing access to new and diverse patient memory B cells to feed the engine Memory B cells: The Most Educated Components of Patient Response Capture memory B cells from Human Immune System cancer or infectious disease patients We see Disease Through the
Slide 7: Infectious Diseases
Infectious Diseases Collaboration with U.S. DoD awarded up to $17.6M in funding Copyright © 2021 Immunome, Inc. All rights reserved.
Slide 8: COVID - Summary
COVID - Summary Current COVID Vaccines and Antibody Therapeutics Not Sufficient • Breakthrough infections despite vaccine use1 • FDA Emergency Use Authorization of antibody therapeutics for treatment of mild to moderate COVID-192 • First-generation antibody therapeutics developed based on virus neut
Slide 9: COVID-19 Vaccines Are Effective, But Not Sufficient
COVID-19 Vaccines Are Effective, But Not Sufficient Resistant Variants • Vaccines targeting original strain elicit reduced levels of antibodies capable of neutralizing emerging variants1 » VOCs evading antibodies against immunodominant epitopes • Infections rising in Western countries despite high v
Slide 10: Emerging Variants Driving Resurgence in Infection Rates and Deaths
U.S. COVID Surge Continues to Lead to Severe Disease New Infections Daily New Infections COVID Surges Despite >50% of U.S. Fully Vaccinated » Approximately 1,500 deaths per day » Cases driven by: 7-Day Average Emerging Variants • Vaccinated but high risk: • Elderly Driving 2019 2021 • Underlying con
Slide 11: Israel Surging Despite Highest COVID-19 Vaccination Rate in the World
Israel Surging Despite Highest COVID-19 Vaccination Rate in the World COVID-19 Will Likely Remain Endemic & Specific Populations Will Continue to be at Risk New Infections Deaths Daily New Infections Daily Deaths 7-Day Average 7-Day Average 2019 2021 2019 2021 Source: www.ourworldindata.org Source:
Slide 12: COVID-19 Therapeutics Will Remain Critical
COVID-19 Therapeutics Will Remain Critical Variants will likely continue to emerge, and may rapidly change the landscape » Delta variant encompasses >99% of all U.S. cases since discovery in April ‘21 » Eta, Iota, Kappa, and Lambda variants are a growing concern Evidence of decreased vaccine coverag
Slide 13: Three Antibody Cocktail Has Multiple Points of Attack and Mechanisms of Action
Three Antibody Cocktail has Multiple Points of Attack and Multiple Mechanisms of Action Bamlanivimab IMM-BCP-01 Regen-CoV AZD7442 Sotrovimab ADG20 & Etesevimab ACE2 Dependent Neutralization Non ACE2 Dependent Neutralization Viral Clearance In vivo Potency Despite Limitations, First Generation Antibo
Slide 14: Immunome's Approach Optimized for Ideal Target Profile
Immunome’s Approach Optimized for Ideal Target Profile Broad Activity Across Variants • Three antibodies directed at non-overlapping/ conserved epitopes provide broad coverage Unique Multimodal MOA • Preclinical evidence of ACE dependent and non- dependent action; three different epitopes. Synergy a
Slide 15: IMM-BCP-01: Mimics the Body's Natural Response
IMM-BCP-01: Mimics the Body’s Natural Response Leverages Unique and Cryptic Epitopes EPITOPE 3: IMM20190 (ACE2 Dependent) EPITOPE 1: IMM20253 • Antibody is a potent ACE2 competitor (Non-ACE2 Dependent) • A composite epitope involving the • Broadly conserved across receptor binding ridge and an area
Slide 16: Superior Preclinical Efficacy and Prophylactic Dose Response vs Sotrovimab
Superior Preclinical Efficacy and Prophylactic Dose Response vs Sotrovimab Sotrovimab IMM-BCP-01 (EUA Approved at 500 mg Dose) • Prophylactic setting (Day -2) in infected hamsters • Treatment setting in infected hamsters • ~3 log clearance at 3 mg/kg • ~ 1.5-log clearance at 5mg/kg • Preclinical pot
Slide 17: IMM-BCP-01 Neutralizes all CDC Variants of Concern in Pseudovirus Testing
IMM-BCP-01 Neutralizes all CDC Variants of Concern in Pseudovirus Testing Neutralization Across Multiple Variants Potent Neutralization of Delta Variant (B.1.617.2) • Alpha, Beta, Gamma, Delta » CDC Variants of Concern (as of 09/20/2021) • Emerging Variants » Delta Plus, Lambda • US and European ref
Slide 18: Viral Clearance is Important, Especially in Immunocompromised Patients
Viral Clearance is Important, Especially in Immunocompromised Patients • Immunocompromised patients exhibit • Prolonged infection leads to emerging prolonged viral load resistant variants Caillard, S., Benotmane, I., Vargas, G. G., Perrin, P., & Fafi-Kremer, S. (2021). SARS-CoV-2 viral dynamics in i
Slide 19: IMM-BCP-01 Clinical Development Plan
IMM-BCP-01 Clinical Development Plan 3 5 Phase 2 IND Filing Phase 1b FIP Study Potential Registration Q4 2021 Dose Ranging Study • Placebo-controlled Potential H2 2022 • Safety, PK, Immunogenicity Phase 1b Extension in Special Population • Treatment and prophylaxis • Safety, PK, viral load Copyright
Slide 20: COVID Antibody Market and Addressable Patients
COVID Antibody Market Addressable Patients REGENERON • High Risk Vaccinated Patients with Breakthrough Infection $2.6B • High Risk Unvaccinated Patients ~$10B IN 2Q 2021 • Immunocompromised Patients (~9M in the US), Including: ADAGIO » Transplant COVID Antibody $3-4B Market » HIV » Chemotherapy ANAL
Slide 21: Oncology
Oncology RESEARCH & DEVELOPMENT • Copyright © 2021 Immunome, Inc. All rights reserved.
Slide 22: Oncology - Summary
Oncology - Summary Highly disruptive platform discovering novel targets based on function-based interrogation of patient memory B-cell response to tumors • Broad, deep and unbiased interrogation • Operating at industrial scale; ~1300 hits, >50 novel targets/antibodies to-date • Platform highlighting
Slide 23: Novel Targets
Novel Targets Antibodies From Patient Memory B-cells Can Reveal Novel Therapeutic Targets Tumor Tumor Antigen Immune Response Antibody Mechanism Tumor killing Control Exosome Post- Growth signaling translational Macrophage modification Mutation T cell T cells activation DC Myeloid cells activation M
Slide 24: Novel Insights from Discovery Engine
Novel Insights from Discovery Engine Systematic Mining of Antibodies Reveal Disease Relevant Functional Clusters A Highly Productive Platform 300,000 1,300 >50 ANTIBODY / HYBRIDOMAS HITS ANTIGEN PAIRS 3 Immune Modulation Novel Provides Critical Insights Into Cancer Biology Such As: Targets Discovery
Slide 25: Immunome Oncology R&D Pipeline
Immunome Oncology R&D Pipeline Targets Identified From Patient Antibodies Program Novel Immune Modulators Potential Cancers of Relevance Stage/Format IMM-ONC-01 Neutralize apoptotic tumor cells derived IL-38; recruit and Lung, head and neck, melanoma, and prostate Development / mAb (Anti-IL-38) acti
Slide 26: IL-38: A Novel Oncology Target
IL-38: A Novel Oncology Target IL-38 Dampens Innate Anti-Tumor Immunity Typical Inflammatory Anti-tumor Response Productive Immune Response IL-38 AGONISTS ANTAGONISTS IL-381 PD-1/PD-L1 IL36a IL36b IL36Ra IL36g IL38 Tumor Microenvironment Autoimmunity Immune Immune Desert Pre-Inflamed Inflamed Exhaus
Slide 27: Clinical Consequences of IL-38 Expression
Clinical Consequences of IL-38 Expression Potential for IL-38 Combination Studies with Existing Therapies Inverse relationship between IL-38 expression Tumor cells secrete IL-38 upon and immune cell infiltration in tumors apoptosis induction • IL-38 secretion associated with apoptotic cell death1 •
Slide 28: IL-38 Expression in Solid Tumors
IL-38 Expression in Solid Tumors IL-38 is expressed in Multiple Tumors of High Unmet Medical Need IL-38 is Expressed in Multiple Tumors of Immunome Data - IL-38 Expression in Primary High Unmet Medical Need Patient Tumors Confirmed by IHC Head & Neck Esophagus Lung, Squamous Cervix Isotype Control A
Slide 29: IMM-ONC-01: Blocking IL-38 Leads to Tumor Control in Two Tumor Models
IMM-ONC-01 Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models Demonstration of Anti-Tumor Activity Induction of Anti-Tumor Memory (B16F10 Model) (EMT6 Model) • Immunologically cold tumor model • ~40% response rate upon treatment with IMM-ONC-01 • IMM-ONC-01 equivalent to best in cla
Slide 30: IMM-ONC-01 Program Summary – Modulating Innate Anti-Tumor Immunity
IMM-ONC-01 Program Summary – Modulating Innate Anti-Tumor Immunity IMM-ONC-01 is a Novel Antibody Candidate Targeting IL-38 • IL-38 is a novel checkpoint in the innate immune system • Targeting IL-38 using IMM-ONC-01 expected to boost anti-tumor immunity • Preclinical research confirms the mechanism
Slide 31: Immunome At A Glance: Proprietary Discovery Engine
Immunome “At A Glance” ADVANCING CLINICAL PROGRAMS IMM-BCP-01 Treatment of COVID-19 IND Submission Q4 2021 • Three antibody cocktail Topline Data H1 2022 • Binds to three non-overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization Proprietary • Potent Effector Function
Slide 32: Thank You
Thank You September 21, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com